



Beta Cell Preservation Work Group Monthly Meeting

February 3, 2026

Agenda

1. Updates on the Commentary
2. Update on JCEM submission plans
3. Update on the White Paper
4. Discussion of measures plans
5. Plans for conference submission for the NCQA Summit

Commentary Updates

- Submitted to Diabetes Technology and Obesity Medicine on January 14th
 - Under review

JCEM Submission Plans

- Dr. Broome will share draft

White Paper Update

- Working with T1DX Marketing Team on a final draft
- Final version will be shared by next week

Discussion of measures plans

Goal:

Integrate new measures into the T1DX-QI Data Specification by end of year 2026

Steps:

- Create a small workgroup to continue existing measures that the Beta Cell Group has identified
- Make clear measure definitions with values, format specifics, format, etc.
- Share proposed changes to the Data Science Committee
- Identify a center to pilot changes (for example, Seattle Children's was a pilot center for integrating Diabetes Distress scale into their reported/mapped data.

Discussion of measures plans

Disease Specific Data							
Variable Number	Variable	Code System	Description	Value	Format	Data Mapping priority	Notes
10	dka_events_inp	t1d	Number of DKA episodes requiring hospitalization since last visit (excludes ED and urgent care visits)	Integer		High	Elevated serum or urine ketones (greater than the upper limit of the normal range) and serum bicarbonate ,15 mmol/L or blood pH ,7.3. Or whatever is routinely documented. ICD10 code for DKA: E10.1 - Type 1 diabetes mellitus with ketoacidosis E10.10 - Type 1 diabetes mellitus with ketoacidosis without coma E10.11 - Type 1 diabetes mellitus with ketoacidosis with coma
11	dka_events_inp_pro	t1d	Patient reported number of DKA episodes requiring hospitalization since last visit (excludes ED and urgent care visits)	Integer		High	Will vary by site's acceptance of PRO
18	dka_serum_bicarb	t1d	Serum bicarbonate level during DKA (mmol/L) to 1 decimal place	Integer	1 Decimal	High	Lab reported serum bicarbonate value in mmol/L associated with a DKA event
19	dka_blood_ph	t1d	Arterial pH value during DKA to 1 decimal place	Integer	1 Decimal	High	Lab reported serum bicarbonate value associated with a DKA event
20	dka_events_pro_dt	t1d	Date of admission for dka_events_inp_pro and dka_events_amb_pro	Date	YYYYMMDD YYYYMM YYYY	High	Patient reported date of when a DKA event occurred for patient reported DKA events

Table of Metrics with ease of reporting

Immunologic	Autoantibody number and type* Repeat testing	Reason declined if No Infections, CBC/CMP
Metabolic	Hemoglobin A1c (%)* CGM Metrics <ul style="list-style-type: none"> •TIR* •Time in Tight Range (TiTR, 70-140 mg/dL) •Time above 140 mg/dL (TA140) •TBR/hypoglycemia* •Glycemic variability - CV* 	>10% TA140 associated with high risk of progression to Stage 3 T1D within 1 year ¹²
Patient Centered	Race/ethnicity* Insurance* BMI* Psychosocial screening* DKA or severe hypoglycemia after DMT*	Patient Centered

NCQA Summit

NCQA topic ideas for the Summit (Beta Cell Preservation: Staging, Screening, and Monitoring Measures)

FYI – for consideration -- NCQA call for speakers for the 2026 Health Innovation Summit is open – proposals due Feb 27.

Session title (85-characters, including spaces)

Full session description (up to 600 words)

Promotional description (up to 200 words)

Clear emphasis on **new innovations, techniques, initiatives, and original approaches**

Describe the **real-world partnership(s)** involved in this work and how the organizations collaborated

List all proposed speakers, ensuring they represent the partnership(s) described, at the time of final submission

Session theme and target audience track

Audience learning level

Explanation of **replication strategies and actionable steps**

Session learning objectives and key takeaways

Application & Impact

The submission provides practical insights, proven strategies or real-world applications based on facts and on **demonstrating how NCQA programs, measures and solutions are applied to drive results** rather than theoretical concepts.

We welcome both successes and challenges—what worked, what didn't, key lessons learned—to provide actionable takeaways.

<https://events.ncqa.org/summit2026/cfs/homepage>





Questions/Comments



T1D

Exchange